Literature DB >> 19877093

Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study.

Mike J L Peters1, Vokko P van Halm, Alexandre E Voskuyl, Yvo M Smulders, Maarten Boers, Willem F Lems, Marjolein Visser, Coen D A Stehouwer, Jacqueline M Dekker, Giel Nijpels, Rob Heine, Ben A C Dijkmans, Michael T Nurmohamed.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD), but longitudinal observations are limited and the precise magnitude is unknown. We prospectively assessed the incidence of CVD in patients with RA compared with patients with type 2 diabetes mellitus (DM) and the general population.
METHODS: The 3-year incidence rate of CVD was determined in a prospective cohort (the Cardiovascular Research and Rheumatoid Arthritis Study) of 353 outpatients with RA, and was compared with that in 1,852 population-based cohort study participants (155 had type 2 DM). We investigated fatal and nonfatal CVD (according to International Classification of Diseases, Ninth Revision criteria) and used Cox proportional hazards models to assess the incidence of CVD in RA, type 2 DM, and the general population.
RESULTS: The 3-year incidence of CVD was 9.0% in patients with RA and 4.3% in the general population, corresponding with an incidence rate of 3.30 per 100 patient-years (95% confidence interval [95% CI] 2.08-4.25) and 1.51 per 100 person-years (95% CI 1.18-1.84), respectively. Compared with the general population, the age- and sex-adjusted hazard ratio (HR) for RA was 1.94 (95% CI 1.24-3.05, P = 0.004). Neither exclusion of patients with prior CVD at baseline nor adjustment for cardiovascular risk factors significantly influenced this. Compared with the nondiabetic population, nondiabetic patients with RA and those with type 2 DM had comparable HRs, 2.16 (95% CI 1.28-3.63, P = 0.004) and 2.04 (95% CI 1.12-3.67, P = 0.019), respectively.
CONCLUSION: The risk of CVD in RA was significantly elevated compared with the general population, and comparable with the magnitude of risk in type 2 DM.

Entities:  

Mesh:

Year:  2009        PMID: 19877093     DOI: 10.1002/art.24836

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  105 in total

Review 1.  Advances in the medical treatment of rheumatoid arthritis.

Authors:  J Michelle Kahlenberg; David A Fox
Journal:  Hand Clin       Date:  2011-02       Impact factor: 1.907

Review 2.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

3.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 4.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

Review 5.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 6.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Cynthia S Crowson; Katherine P Liao; John M Davis; Daniel H Solomon; Eric L Matteson; Keith L Knutson; Mark A Hlatky; Sherine E Gabriel
Journal:  Am Heart J       Date:  2013-08-29       Impact factor: 4.749

7.  Recognition and control of hypertension, diabetes, and dyslipidemia in patients with rheumatoid arthritis.

Authors:  Luísa Lima Castro; Cristina Costa Duarte Lanna; Mariana Pimenta Rocha; Antônio Luiz Pinho Ribeiro; Rosa Weiss Telles
Journal:  Rheumatol Int       Date:  2018-06-15       Impact factor: 2.631

Review 8.  Use of DXA-based technology for detection and assessment of risk of vertebral fracture in rheumatology practice.

Authors:  Michael Maricic
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

Review 9.  Co-morbidity index in rheumatoid arthritis: time to think.

Authors:  Yasser El Miedany
Journal:  Clin Rheumatol       Date:  2015-10-26       Impact factor: 2.980

10.  Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!

Authors:  Ulf Müller-Ladner; Ingo H Tarner; Christian Hamm; Uwe Lange
Journal:  F1000 Med Rep       Date:  2010-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.